Roche Succeeds In Changing EMA Ruling On Avastin
This article was originally published in The Pink Sheet Daily
Executive Summary
The Committee for Medicinal Products for Human Use has reversed its previous rejection and is granting an indication for treatment of first-line breast cancer in combination with capecitabine.
You may also be interested in...
Pfizer Pulls Celebrex's FAP Indication Quickly After Slow Trial Results
The European Medicines Agency issues a formal review, even though the claim had been withdrawn, in order to discourage off-label use.
Pfizer Pulls Celebrex's FAP Indication Quickly After Slow Trial Results
The European Medicines Agency issues a formal review, even though the claim had been withdrawn, in order to discourage off-label use.
Genentech, CDER Spar Over Third-Party Views On Avastin Breast Cancer Claim
Disagreements between Genentech and FDA’s Center for Drug Evaluation and Research over the scope of evidence to be allowed at the June 28-29 hearing on Avastin’s breast cancer indication have escalated into a heated debate over the relevance of external views.